Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

American Journal of Cardiology

Volumn 89, Issue 3, 2002, Pages 268-275

  Davidson, Michael ^a   Ma, Patrick ^b   Stein, Evan A ^c   Gotto Jr , Antonio M ^d   Raza, Ali ^e   Chitra, Rohini ^e   Hutchinson, Howard ^e  

^a RADIANT RESEARCH   (United States)

^b Heart Health Institute   (Canada)

^c Metabolic and Atherosclerosis Research Center   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CANADA; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0036467895     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02226-3     Document Type: Article

References (25)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
2. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
4. Drug treatment of lipid disorders
5. Comparative dose efficacy study of atorvastatin versus simvastatin pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
6. Comparison of 1-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
7. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
8. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
9. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
10. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
11. Pharmacological properties of ZD4522: A new HMG-CoA reductase inhibitor
12. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522
13. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Research Clinics' methodology
14. Effects of lyophilization of serum on the measurement of apolipoproteins A-I and B
15. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: III: Comparability of apolipoprotein A-I values by use of international reference material
16. A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB
17. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements
18. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
19. Lipid, and lipoprotein analysis
20. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
21. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study
22. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study
23. Cholesterol in the prediction of atherosclerotic disease: New perspectives based on the Framingham study
24. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
25. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)